DNL (MCap £31 M) 2 Big Drugs close to EMA & FDA approval = MEGA Opp

Biomonster

Junior member
21 0
The most underpriced and attractive british biotech company with MASSIVE upside potential .Still think this sleeping giant has 10+ bagger upside potential and 2020 could be the year for DNL with all the approvals and partnerships expected during the year .GL



Diurnal (DNL)
Market Cap £24 M
Price: 29p


DCF valuation of 202p per share

Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses

Presentation


Upcoming Catalysts:

US-NDA acceptance for Alkindi in Februry 2020

MAA-Acceptance for Chronocort in February/March 2020

Alkindi approval in Israel expected in 1Q 2020

Alkindi approval in Australien expected in 2Q 2020

US-Partnership for Alkindi & Chronocort expected in 1H 2020

Alkindi & Chronocort Partnership for Asia für Japan und China

US-Approval for Alkindi expected in 4Q 2020

EU Approval for Chronocort expected in 4Q/1Q 2020/21


$88m market opportunity (Europe and US) for Paediatric AI (inc CAH)
$351m market opportunity (Europe and US) for Congenital Adrenal Hyperplasia
$2,767m market opportunity (Europe and US) for Adrenal Insufficiency



Ceo bought another 25k shares at 30p
 

Biomonster

Junior member
21 0
GREAT News out today ..NDA accepted by FDA and the Drug could be approved in Q3 .. Still the CHEAPEST and most attractive small cap Biotech in UK . A potential 10 Bagger here


Diurnal : US FDA Accepts NDA Application for Alkindi

Application seeks approval of Alkindi® Sprinkle as a replacement therapy of adrenal insufficiency in infants, children and adolescents

NDA could potentially be approved in Q3 2020



Diurnal (DNL)
Market Cap £23 M
Price: 28p


New Presentation
 

Biomonster

Junior member
21 0
DNL =BIG Drug with potential FDA approval in 2 months = 5+ BAGGER GEM

Diurnal Group (DNL) = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping iant here .GL

Market Cap £38 million
Cash £15 million
Price 30p


Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021
 

Biomonster

Junior member
21 0
Stock hit new 52W high yesterday .....

A LOT of BIG milestones are around the corner which likely will push the stock toward 200p and higher . The most important milestones are the FDA Decision for Alkindi in September and the EMA Decision for Chronocort in early Q1 . STRONG BUY stock likely to run higher as we move closer to US-FDA approval .

Valuation 344p

The increased use of commercial partners has caused us to reassess our DCF analysis, moving it more towards a distribution and royalty-based model. Our original DCF valuation,based on clearly stated assumptions,was published on 25 April 2019.The NPV of the cash flows that could be generated from DNL’s first two products has changed from £389m to £455m.Risk-adjustment to take account of the different stages of development in different territories reduces this to £298m, or 344p per share

Market Cap £76 million
Cash balance £15 million or Cash untill end 2021
Price 62 p

Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29 ( DNL will receive $2.5 M on first commercial sale expected in Q4 )
EMA Decision for Chronocort expected in early Q1 2021
US-Partnership for Chronocort (Phase 3 ready) in 2H 2020
 
 
AdBlock Detected

We get it, advertisements are annoying!

But it's thanks to our sponsors that access to Trade2Win remains free for all. By viewing our ads you help us pay our bills, so please support the site and disable your AdBlocker.

I've Disabled AdBlock